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Key Clinical Message
Susceptibility to quinoline antimalarial intoxication may reflect individual genetic
and drug-induced variation in neuropharmacokinetics. In this report, we describe
a case of chloroquine intoxication that appeared to be prolonged by subsequent
use of multiple psychotropic medications. This case highlights important new
considerations for the management of quinoline antimalarial intoxication.
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Introduction
Currently available synthetic quinoline antimalarials,
including chloroquine, exhibit idiosyncratic neuropsychi-
atric effects when administered at low doses used for che-
moprophylaxis. Idiosyncratic cases of acute intoxication
from quinoline antimalarials have been well characterized
in the literature since the first widespread use of the now-
outmoded synthetic quinoline quinacrine (also known as
atabrine) in the mid-1940s [1, 2]. With subsequent wide-
spread use of chloroquine, a drug developed as a less
toxic replacement for quinacrine [3], similar idiosyncratic
cases of intoxication [4–6] were soon reported. More
recently, similar intoxicating effects from mefloquine,
itself developed as a replacement for chloroquine [7],
have become well characterized in the literature [8].
Although the naturally occurring quinoline antimalarials
have traditionally been considered free of such effects,
cases of a related syndrome of intoxication have also
occasionally been reported after relatively low doses of
quinine [9, 10] and quinidine [11, 12], suggesting a com-
mon intoxicating class effect.
Descriptions of chloroquine intoxication in the litera-
ture, commonly characterized as toxic psychosis, are simi-
lar to those associated with other quinolines and typically
feature insomnia [13, 14], mania [15, 16], paranoia and
persecutory delusions [17], and auditory and visual hallu-
cinations [18]. Symptoms of intoxication may resemble
those of brief psychotic disorder but are more likely to
include prominent visual hallucinations, anxiety, restless-
ness, agitation, and derealization [19]. Suicidality is not
uncommon reported [20], and reports of completed sui-
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cide [21, 22] attest to the potentially life-threatening nat-
ure of such intoxication. Other symptoms of intoxication
may include impulsivity, over-talkativeness with flight of
ideas, unprovoked laughing or crying [20], personality
change, grandiosity, depersonalization [6], and delusional
misidentification [23].
Occasionally, intoxication may also induce a delirium
[24] or encephalopathy whose symptoms may include
confusion [25], difficulties with concentration [26], mem-
ory loss and amnesia [27], and catatonia [28].
Although theories have been proposed to explain quin-
oline intoxication [29, 30], the precise pathophysiological
basis of these effects remain unclear despite numerous
molecular mechanisms having been identified experimen-
tally. Antimalarial quinolines typically cross the blood–
brain barrier to concentrate within the central nervous
system (CNS) [31], where many have been demonstrated
to directly affect chemical synaptic communication [32],
including at serotonin [32, 33], adenosine [34], gamma-
amino butyric acid (GABA) [35], and opioid [36] recep-
tors. Various quinolines have also been identified as
potent inhibitors of interneuronal electrical communica-
tion [37] and are suspected of disrupting transmission
between networks of GABA inhibitory interneurons [38,
39]. Such drug-induced inhibitory dysfunction may be
sufficient to induce a toxic encephalopathy that mimics
in particular the limbic effects of anti-N-methyl-D-aspar-
tate receptor (NMDA) receptor hypofunction [40].
As with other causes of intoxication delirium [41],
which may induce neurological abnormalities [24], chlo-
roquine intoxication has been associated with certain
extrapyramidal-like movement disorders including stereo-
typical repetitive movements [42], ataxia [43], facial dys-
tonia and torticollis [44, 45], dysphonias [45], oculogyric
dystonia [46], and other neurological effects [47] includ-
ing tinnitus, vestibulopathy, and accommodative dysfunc-
tion [48]. While many symptoms of quinoline
intoxication delirium are seemingly reversible with elimi-
nation of the drug, use of various quinolines has also
been associated with the development of chronic neuro-
logical disorders including temporal lobe epilepsy [49],
dysautonomia [50], and central vestibulopathy [40]. In
addition to reflecting the direct sequelae of encephalopa-
thy, drug-induced brain and brainstem neurotoxicity may
underlie at least some prolonged neuropsychiatric effects
[51]. For example, in animal models many drugs of the
class induce highly focal neurotoxic lesions throughout
multiple brain and brainstem areas including the medulla,
pons, striatum, and limbic system [51]. Chloroquine may
also induce histopathological alterations within multiple
neuron subtypes in CNS including within the brainstem
and limbic system [52, 53]. In this regard, similarities in
the chronic neuropsychiatric sequelae from the antimalar-
ial quinolines shared to a degree with the effects of even
the minimally substituted antiparasitic quinoline clioqui-
nol [49, 54] may suggest either neurotoxicity from an
as-yet uncharacterized common metabolite, or a direct
dose-dependent neurotoxic effect shared among drugs of
the class.
Similarly, as neuropsychiatric effects that occur with
low doses of quinoline antimalarials during chemopro-
phylaxis mimic effects more reliably produced at higher
doses or dose rates with use in treatment, susceptibility to
intoxication and subsequent neurotoxicity during chemo-
prophylaxis may reflect multifactorial genetic and drug-
induced variations in neuropharmacokinetics which may
serve to locally increase such metabolite or drug concen-
trations in brain [51] despite normal serum levels.
In this report, we describe a case of quinoline intoxica-
tion that developed while taking low dose chloroquine as
chemoprophylaxis that was further exacerbated by the
addition of various psychotropic agents used to manage
neurobehavioral symptoms associated with the acute intox-
ication. Pharmacogenetic testing was consistent with absent
enzymatic activity of cytochrome P450 (CYP) 2D6, as well
as potentially altered activities of CYP1A1, CYP1A2,
CYP2C8, CYP2C9, CYP2C19, and P-glycoprotein (P-gp, or
ABCB1). In this report, the possible role of these polymor-
phisms in contributing to susceptibility to chloroquine
intoxication, as well as in prolonging its neuropsychiatric
sequelae in the context of psychotropic polypharmacy are
discussed together with new considerations for appropriate
clinical management of this condition.
Case History
While volunteering in Honduras, a 16-year-old female
with an unremarkable medical history became ill during
her ninth week of chloroquine prophylaxis (250 mg
weekly). She had begun malaria prophylaxis 2 weeks prior
to travel, and by her seventh week in Honduras had
developed insomnia, paranoia, and confusion that pro-
gressed in severity over the next 2 days. Following a dose
of diphenhydramine to aid sleep, her symptoms pro-
gressed to include hallucinations, irrational guilt and self-
persecution, suicidal ideation, and catatonic features. She
was taken to a local neurologist where initial workup
revealed a normal head CT, unremarkable lumbar punc-
ture, normal complete blood count, negative infectious
disease studies, and negative urine toxicology screen.
Upon repatriation to the United States 2 days later, she
was admitted to the emergency room of a local hospital
where olanzapine and lorazepam were administered for
acute management of behavioral symptoms. Upon hospital
admission, risperidone and fluoxetine were initiated with
lorazepam continued on an as-needed basis for anxiety. On
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the second day, benztropine was added while lorazepam
was replaced with clonazepam. Her mental status improved
briefly by the evening of the second hospital day and she
was able to converse with her family and recall many of her
experiences over the prior week. However, by the morning
of the third day, she had slipped back into a state of marked
confusion, self-persecution, paranoia, suicidal ideation,
visual and auditory hallucinations, delusional thinking, and
catatonia. These progressed in a waxing and waning man-
ner over the next 14 days.
Differential Diagnosis,
Investigations, and Treatment
Although chloroquine intoxication was considered in the
differential diagnosis, owing to the severity of symptoms
and their similarity to those of NMDA receptor
(NMDAR) encephalitis [55], cerebrospinal fluid (CSF)
collected in Honduras was sent for NMDAR antibody
titers, but these were found to be negative. Two addi-
tional lumbar punctures were performed over the course
of the first 17 hospital days, but these repeat NMDAR
antibody titers were also negative. As an additional pre-
caution, an abdominal ultrasound was performed which
ruled out ovarian tumors often found in NMDAR
encephalitis [56]. CSF samples from each of these collec-
tions were also sent to the California Encephalitis Project
[57] for additional viral studies but were also negative. A
head MRI was normal. A video-EEG was attempted but
the patient would not cooperate. Beta-human chorionic
gonadotropin (b-HCG) was negative, serum copper was
normal, and serum porphyrins were low. Urine toxicol-
ogy, porphyrins, and heavy metals were all normal. Infec-
tious disease studies revealed a positive serum IgM but
negative IgG for Brucella and a positive serum IgM for
Mycoplasma pneumoniae, for which she was treated with a
standard dose of azithromycin daily for 5 days. Rheuma-
tologic disease studies were remarkable for a mild eleva-
tion in erythrocyte sedimentation rate and thyroglobulin
antibody, but normal C-reactive protein. A neurologic
exam on hospital day 17 revealed extreme mydriasis,
amaurosis, patellar areflexia, dysphonia, and facial palsies.
Despite worsening neurological findings and mental
status, the absence of evidence of a treatable organic cause
and the need to manage continued symptoms led to
transfer to a psychiatric hospital 3 days later. At the time
of transfer, she exhibited near-catatonic features. The fol-
lowing day, risperidone, benztropine, and fluoxetine were
replaced with olanzapine and lorazepam. Over the next
3 days, she improved remarkably. However, after the
fourth day she progressively declined with increasing
visual illusions, extreme paranoia with magical and delu-
sional thoughts (e.g., each of the staff were interpreted as
celebrities, and she believed a bird outside the window
was videotaping her and that she was imprisoned in a
foreign country), suicidal ideation and anxiety. She dem-
onstrated a return of facial palsies and abnormal phona-
tion as her dose of olanzapine was increased from 2.5 mg
to 17.5 mg daily. The correlation of medication dosage
with symptom severity raised suspicion for an exacerba-
tion of toxicity from psychotropic polypharmacy. By hos-
pital day 58, olanzapine was tapered off, after which she
rapidly improved and was discharged on hospital day 66
on a single tapering dose of lorazepam only. Outpatient
neuro-ophthalmologic exam revealed findings of extreme
mydriasis, despite the patient not having been on an anti-
cholinergic medication for over 45 days. This led to sus-
picion that abnormal medication metabolism was
contributing to central anticholinergic toxicity.
Pharmacogenetic testing was then obtained using the
Drug Metabolizing Enzymes and Transporters (DMET)
DNA Microarray GeneChip [58], with selected polymor-
phisms confirmed by direct analysis at the Mayo Clinic
Laboratories. Results (Table 1) were consistent with absent
CYP2D6 activity [59], and potentially altered CYP1A1,
CYP1A2, CYP2C8, CYP2C9, CYP2C19, and ABCB1 activi-
ties. Samples of urine, serum, and CSF that were stored
over the course of hospitalization at the California
Encephalitis Project were later retrieved and analyzed for
the presence of chloroquine and its metabolite. Their pres-
ence was confirmed and concentrations of chloroquine in
serum were found to be within the expected range [60].
Outcome and Follow-up
The patient convalesced at home off all medications over
the next 4 months. She underwent extensive neuropsy-
Table 1. Selected Positive Cytochrome P450 (CYP) and ATP-binding
cassette (ABC) Single Nucleotide Polymorphisms (SNP).
Gene SNP
Reference SNP
(rs) ID
Observed
Alleles Notes
ABCB1 -25G>T rs2235015 T/T 1
24G>A rs2235040 A/A 1
CYP1A1 2452C>A rs1799814 C/A 1
CYP1A2 -163C>A rs762551 A/A 1,2
CYP2C8 30411A>G rs10509681 A/G 1
CYP2C9 430C>T rs1799853 C/T 2
CYP2C19 2608C>T rs10509681 C/T 1
-806C>T rs12248560 C/T 1,2
CYP2D6 1846G>A rs3892097 A/A 1,2
100C>T rs1065852 T/T 1,2
1661G>C rs1058164 C/C 1
4180G>C rs1135840 C/C 1
1. From DMET DNA Microarray GeneChip.
2. From direct polymorphism analysis.
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chological testing but no localizing deficits could be
identified. She then returned to high school where she
was noted by family and friends to have experienced fur-
ther behavioral changes (e.g., baseline introversion gave
way to extroversion with excessive use of cellphone and
social media and attention-seeking behavior), attention
deficit-like symptoms (e.g., diminished attention, concen-
tration) and uncharacteristic learning deficits. During her
final exams, she decompensated in apparent exhaustion.
Thereafter, she began to demonstrate increasingly bizarre
behavior including: periods of catatonic-like features (e.g.,
often sitting for hours and staring at herself in the mir-
ror), punctuated by hysterical fits of inappropriate laugh-
ter. She exhibited ritualistic semiconscious behavior that
seemed to appear each evening, with associated insomnia.
She reported vague but intense pains in the throat and
genitalia. Workups aimed at identifying organic causes of
these pains were negative. Attempts at providing an ideal
environment for her to rest and sleep failed as her insom-
nia and declining behavior progressed.
The patient’s prolonged neuropsychiatric symptoms
were suspected to represent sequelae of chloroquine
intoxication encephalopathy. Specialists in quinoline tox-
icity and psychopharmacology were consulted, and in
addition to limbic encephalitis, suspicion of quinoline-
induced limbic [49], and brainstem [8] neurotoxicity with
possible associated epilepsy or nonconvulsive status epi-
lepticus [61] and neuralgias were also raised. Certain
organic causes were again ruled out following a repeat
MRI and lumbar puncture that were normal, and CSF
sent for a broad panel of midbrain receptor autoantibody
titers returning negative. A 48-hour, continuous video-
EEG monitoring was also negative for cortical seizures.
Guided by the newly obtained pharmacogenetic testing,
a new medication regimen directed at managing her neuro-
psychiatric symptoms and central cholinergic hypoactivity,
and to empirically manage a possible occult seizure disor-
der was designed. To these effects, valproic acid, paliperi-
done, and rivastigmine were sequentially initiated. On the
third day of valproic acid, an abrupt improvement in men-
tal status occurred whereby the bizarre behavior subsided
and the patient was able to engage in detailed conversations
on a wide range of topics. The sequential additions of pali-
peridone followed by transdermal rivastigmine appeared to
add small incremental improvements in her cognition,
mental status, and behavior. None of these medications ini-
tially appeared to lead to any adverse effects.
After a few weeks, the patient’s behavior had signifi-
cantly improved and she was weaned off paliperidone.
After a few months, she was weaned off valproic acid
while continuing on transdermal rivastigmine only. She
convalesced at home for 4 months and returned to finish
high school without any behavioral issues but with
emerging symptoms of extreme fatiguability, orthostatic
intolerance, and attentional deficit all suggestive of the
autonomic dysfunction following brain injury [62]. Con-
cerns for rivastigmine contributing to these lingering
symptoms led to its substitution with a subsequent grad-
ual taper of an oral formulation that continued through
the end of reported follow-up, 36 months after the initial
intoxication.
Discussion
While this patient’s initial symptoms were remarkably
consistent with those in other reports of quinoline intoxi-
cation and specifically in prior reports of chloroquine
intoxication [6, 14, 15, 17, 20, 25, 42, 63], the extended
nature of certain neuropsychiatric effects has not previ-
ously been reported with this drug. In this case, pharma-
cogenetic testing revealed evidence of absent CYP2D6
activity, alterations in the activity of at least five other
enzymes including CYP1A1, CYP1A2, CYP2C8, CYP2C9,
and CYP2C19 involved in the metabolism either of chlo-
roquine or the psychotropic drugs used to manage her
symptoms, and evidence of altered P-gp activity. While
these pharmacogenetic findings do not provide definitive
insight into the etiology of the patient’s original intoxica-
tion, they do suggest that it may have been a direct effect
of an inability to metabolize chloroquine. Likewise, these
pharmacogenetic findings may provide pharmacokinetic
explanations for the extended duration of at least some of
her symptoms. The plausible pharmacogenetic correlates
in this case therefore raise important new considerations
for the management of quinoline antimalarial intoxica-
tion.
Etiology
In this case, the patient exhibited characteristic symptoms
of quinoline intoxication, including insomnia, paranoia,
and confusion well prior to use of any other psychotropic
drugs. This suggests that the etiology of this intoxication
could reflect a primary genetic susceptibility to these
effects. For example, genetic susceptibility to mefloquine
intoxication has been postulated to primarily reflect poly-
morphisms in ABCB1 [64, 65]. However, although chlo-
roquine is a potent P-gp inhibitor [66], there is yet little
direct evidence that the drug is a significant P-gp sub-
strate in vitro [66]. Therefore, whatever alteration in
activity might be associated with the homozygous varia-
tion in ABCB1 (rs2235015 and rs2235040) observed in
this case may not have directly contributed to risk of ini-
tial intoxication. Conversely, among other enzymes with
polymorphisms suggesting altered activity, CYP1A1,
CYP1A2, CYP2C8, and CYP2C19 are all believed to be
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involved in chloroquine metabolism [67, 68]. Our patient
was found to have heterozygous variation in CYP1A1
(rs1799814), CYP2C8 (rs10509681), and CYP2C19
(rs12248560), and homozygous variation in CYP1A2
(rs762551), but the clinical significance of these in the
context of chloroquine metabolism is not clear based on
existing studies.
The only enzyme in which a well-characterized alter-
ation in activity was identified in our patient was
CYP2D6. Although prior reports have suggested that
chloroquine is not significantly metabolized in vitro by
CYP2D6 [67], it is plausible that brain-specific variations
in CYP2D6 expression might play a relevant role in the
etiology of chloroquine intoxication in vivo. Of the major
isoforms thus far found responsible for chloroquine
metabolism, only CYP2D6 is known to be relatively more
expressed than these isoforms in brain relative to liver
[69]. Interestingly in this respect, the proportion of sub-
jects who are found to lack CYP2D6 activity [70], typi-
cally 10% or fewer, is similar to the proportion of
subjects in studies of chloroquine prophylaxis who report
prodromal psychiatric symptoms such as depression, irri-
tability, and confusion [71], which may predict risk of
more serious intoxication with continued dosing.
In this case, it may be hypothesized that if brain-
specific expression of chloroquine-metabolizing CYP
isoforms is necessary to mitigate the risk of intoxication,
the absence of CYP2D6 activity might in part explain the
observed susceptibility. According to this hypothesis, the
addition of fluoxetine, a potent CYP2D6 inhibitor [72],
administered during the first 20 days of hospitalization,
may have potentially further reduced whatever minimal
chloroquine metabolic activity may have been initially
present in brain tissue.
Whether or not the hypothesis is correct that the
absence of CYP2D6 mediated metabolism of chloroquine
in brain may have been primarily responsible in this case
for the initial intoxication and its extended duration, it is
tempting to speculate that the absence of CYP2D6 activity
may also have contributed through other mechanisms to
the extended duration of illness. CYP2D6 provides a
major pathway for the metabolic inactivation of many of
the drugs to which the patient was subsequently exposed,
including diphenhydramine [73] used to manage initial
symptoms of insomnia, as well as the risperidone [74],
fluoxetine [75], and benztropine [76] employed during
subsequent hospitalization. In the absence of metabolic
inactivation, their potential accumulation to toxic levels
may have further complicated clinical presentation. For
example, among those with absent CYP2D6 activity and
treated with risperidone, a case report has described pro-
longed neurologic side effects including extrapyramidal
movement disorders [74], whereas among those treated
with fluoxetine, another case report has described pro-
longed neurologic side effects including incoordination,
ataxia, and seizure [75]. Certain of these side effects
might have readily confounded the presentation of chlo-
roquine intoxication had they indeed occurred in our
patient.
Clinical application
While pharmacogenetic testing allowed the treatment
team to recognize the potential contribution of polyphar-
macy to the patient’s original intoxication, this may have
remained of little more than academic interest had it not
been for the latent relapse necessitating further treatment.
Once symptoms returned, an understanding of the poten-
tial contributions of pharmacogenetics to the etiology of
her illness aided the treatment team in selecting appropri-
ate therapy.
Antiepileptic agents have been successfully employed in
the management of multiple neurological sequelae of
brainstem [77] and limbic encephalitis, which may serve
as a reasonable pathophysiological model for the brain
and brainstem injury [8, 51] that may follow quinoline
intoxication encephalopathy [40]. With knowledge of the
possibility of a nonconvulsive status as causative or con-
tributory to the waxing and waning presentation, valproic
acid was chosen to manage symptoms demonstrated by
the patient. Other reasons for its selection included its
neuroprotective properties [78, 79], and its efficacy in
managing agitation and psychotic symptoms associated
with acute confusional states [80, 81]. Whether or not
this presumed etiology was correct, the patient seemed to
have a dramatic response in mental status by the third
dose of valproic acid. Unlike certain other antiepileptic
agents, valproic acid is not significantly metabolized by
CYP2D6 [82], making it a reasonable choice given the
absent activity of this enzyme.
Additionally, paliperidone was also selected to manage
the patient’s psychotic symptomatology, given its lack of
associated CYP metabolism, absence of anticholinergic
activity, and minimal sedation and extrapyramidal symp-
toms [83]. Finally, given evidence suggestive of a dysau-
tonomia and central anticholinergic state, rivastigmine
[84] was selected in an attempt to enhance central cholin-
ergic activity.
In addition to informing management of individual
future cases of intoxication, this case also highlights the
important emerging role of pharmacogenetic testing in
the routine prescribing of antimalarial quinolines.
Recently, metabolism by CYP2D6 has been shown to be
necessary in ensuring reliable antimalarial effects from the
related antimalarial primaquine [85]. As standard phar-
macogenetic testing becomes ever more widely available,
ª 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 383
N. M. Maxwell et al. Prolonged effects following chloroquine intoxication
the assessment of CYP2D6 activity may soon help to
inform consideration of alternatives to primaquine in the
chemoprophylaxis of malaria disease [86]. However,
should the increased risk of neuropsychiatric toxicity
among those with reduced CYP2D6 activity hypothesized
in this case be found to be shared among other quino-
lines, this would preclude increasing the dosing of these
and related drugs [87] as a safe strategy for overcoming
reduced antimalarial effects.
Conclusions
This case suggests important new considerations for the
appropriate clinical management of quinoline antimalarial
intoxication. Given the generally self-limiting nature of
most acute symptoms of quinoline intoxication, clinicians
managing future cases may wish to avoid psychotropic
polypharmacy. This may potentially avoid prolonging the
duration of acute symptoms and may reduce the risk of
chronic neuropsychiatric sequelae; both of which may be
plausibly linked to individual genetic and drug-induced
variation in neuropharmacokinetics.
This case also points to a need for quinoline antimalar-
ial drug development, including prelicensing trials assess-
ing safety and efficacy, to be informed by relevant
pharmacogenetic testing among enrolled subjects.
Lastly, this case also emphasizes the critical need for
those reporting neuropsychiatric adverse events from anti-
malarial quinolines to include, wherever possible, the
results of standard pharmacogenetic testing panels that
include the enzymatic pathways plausibly involved in the
neuropharmacokinetics of these drugs.
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